Host Fred Goldstein invites Dr. Emmanuel Mensah, a Firm Chief and Faculty at Beth Israel Deaconess Medical Center / Harvard Medical School to discuss taking a look in the mirror and reflect on our own implicit biases and disparities in health care.
Host Fred Goldstein invites Jim Hopsicker, AMCP President & Vice President, Health and Pharmacy Management at MVP Health Care, Inc., and Susan Cantrell, AMCP CEO, to discuss the state of AMCP Priorities.
Host Fred Goldstein invites Adam Colborn, Director, Government Affairs at AMCP to discuss AMCP Federal Legislative Priorities on this second episode of a two part discussion.
• On Nov. 6, 2023, the Centers for Medicare and Medicaid Services (CMS) issued a
memorandum titled Application of Pharmacy Price Concessions to the Negotiated
Price at the Point of Sale Beginning Jan. 1, 2024 (Memo).
The world of prescription drug care and coverage can be complicated. Read AMCP CEO Susan Cantrell’s blog on AMCP’s inaugural “Access, Affordability, & Outcomes: The Value of Managed Care Pharmacy” annual report to learn how we’re making it more understandable
With October devoted to National Pharmacy Awareness, AMCP CEO Susan Cantrell talks about the outstanding efforts of managed care pharmacists across the United States in her latest blog.
The Biologics & Biosimilars Collective Intelligence Consortium (BBCIC) today announced that it has been awarded a $1.4 million grant from the Food & Drug Administration (FDA) to enable biosimilar research.
Managed care pharmacy and prescription drug coverage is a growing part of the American health care sector. AMCP launched the annual Access, Affordability, and Outcomes report to raise awareness of the existence, prevalence, and importance of managed care pharmacy.
Due to the COVID-19 PHE, flexibilities were implemented to prevent lapses in
patient care by allowing the prescribing of schedule II-V controlled medications via
audio-video telemedicine encounters – including schedule III-V narcotic controlled
medications approved by the Food and Drug Administration (FDA) for
maintenance and withdrawal management of opioid use disorder – even when the
prescribing practitioner had not conducted an in-person medical evaluation of the
patient.
